{"transactions":[{"id":976284,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":71990,"kind":"person","name":"Kress Jean-Paul","position":1,"cik":"0001654979","reported_name":"Kress Jean-Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-09T13:00:07.000Z","date":"2025-12-05","kind":"grant","planned":false,"acquired":true,"shares":4164831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":4164831,"derivative":{"exercise_price":8.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":4164831},"source":{"system":"sec-edgar","filing":"0001654979-25-000006","document":"form4-12092025_081201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000165497925000006/form4-12092025_081201.xml","form_type":"4"}},{"id":976283,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":71990,"kind":"person","name":"Kress Jean-Paul","position":1,"cik":"0001654979","reported_name":"Kress Jean-Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-09T13:00:07.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4164831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split."}],"balance_after":0,"derivative":{"exercise_price":17.8,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":4164831},"source":{"system":"sec-edgar","filing":"0001654979-25-000006","document":"form4-12092025_081201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000165497925000006/form4-12092025_081201.xml","form_type":"4"}},{"id":1100341,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":71990,"kind":"person","name":"Kress Jean-Paul","position":1,"cik":"0001654979","reported_name":"Kress Jean-Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-06-27T20:10:08.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":83296638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":83296638,"derivative":{"exercise_price":0.89,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":83296638},"source":{"system":"sec-edgar","filing":"0001415889-25-018365","document":"form4-06272025_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925018365/form4-06272025_080605.xml","form_type":"4"}},{"id":4266143,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":71990,"kind":"person","name":"Kress Jean-Paul","position":1,"cik":"0001654979","reported_name":"Kress Jean-Paul","relationship":{"officer":true,"officer_title":"EVP Pres Int'l & Global Hd GTO"}}],"security":"Restricted Stock Unit","published_at":"2017-07-05T23:18:43.000Z","date":"2017-07-03","kind":"grant","acquired":true,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":4660,"derivative":{"exercise_price":0,"expiration_date":"2020-07-03","underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001127602-17-023131","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217023131/form4.xml","form_type":"4"}},{"id":4387327,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":71990,"kind":"person","name":"Kress Jean-Paul","position":1,"cik":"0001654979","reported_name":"Kress Jean-Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-03-15T01:42:47.000Z","date":"2017-03-10","kind":"grant","acquired":true,"shares":12350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders."}],"balance_after":12350,"derivative":{"exercise_price":32.63,"expiration_date":"2027-03-10","underlying":"Common Stock","underlying_shares":12350},"source":{"system":"sec-edgar","filing":"0001209191-17-020684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117020684/doc4.xml","form_type":"4"}},{"id":4387326,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":71990,"kind":"person","name":"Kress Jean-Paul","position":1,"cik":"0001654979","reported_name":"Kress Jean-Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-15T01:42:47.000Z","date":"2017-03-10","kind":"grant","acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-17-020684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117020684/doc4.xml","form_type":"4"}}]}